Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 3 Distribution of patients with and without nuclear expression of programmed cell death protein 1 ligand 1 in peritumoral lymphocytes, n (%)

Breast cancer characteristics	Nuclear expression of PDCD1 LG1 in peritumoral lymphocytes		P value χ² tests
	Absent	Present
T stage
Т in situ	0 (0)	4 (100)	0.69
Т1в	2 (18.2)	9 (8.18)
Т1с	12 (13.5)	77 (86.5)
Т2	4 (9.1)	40 (90.9)
N stage
N0	8 (9.9)	73 (90.1)	0.57
N1	8 (17.0)	39 (83.0)
N2	2 (12.5)	14 (87.5)
N3	0 (0)	4 (100)
Tumor grade (G)
G1	4 (25.0)	12 (75.0)	0.15
G2	8 (8.8)	83 (91.2)
G3	6 (14.6)	35 (85.4)
Lymphovascular invasion
No	6 (7.1)	78 (92.9)	0.03
Yes	12 (18.8)	52 (81.2)
Perineural invasion
No	12 (10.4)	103 (89.6)	0.23
Yes	6 (18.2)	27 (81.8)
ER status
Negative	0 (0)	16 (100)	0.11
Positive	18 (13.6)	114 (86.4)
PR status
Negative	10 (24.4)	31 (75.6)	0.004
Positive	8 (7.5)	99 (92.5)
HER2 status
HER2-	18 (14.1)	110 (85.9)	0.07
HER2+	0 (0)	20 (100)
Molecular biological subtype
Luminal A	6 (10.7)	50 (89.3)	0.20
Luminal B HER2-	12 (18.2)	54 (81.8)
Luminal B HER2+	0 (0)	10 (100)
Nonluminal HER2+	0 (0)	10 (100)
TNBC	0 (0)	6 (100)

ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; PDCD1 LG1: Programmed cell death protein 1 ligand 1; TNBC: Triple-negative breast cancer.